Abstract:Background. The most effective treatment of immune checkpoint inhibitors (ICIs) is restricted in microsatellite instability (MSI-H) subsets of advanced colorectal cancer, but MSI-H only accounts for 4-5% among them. ICIs are completely ineffective in advanced colorectal cancer patients with microsatellite stable (MSS), according to literatures published. Regorafenib is a novel tyrosine kinase inhibitor (TKIs) that could normalize tumor blood vessels by inhibiting vascular endothelial growth factor receptor and its downstream, thus improving cytotoxic T cell infiltration in tumor microenvironment, which has a synergistic effect with ICIs. Toripalimab is a type of anti-PD-1 monoclonal antibody produced by Junshi Biosciences in China. Herein, we aimed to explore the efficacy and safety of regorafenib combined with toripalimab in the third-line and beyond treatment of advanced colorectal cancer. Methods. We evaluated the outcomes of MSS patients with advanced colorectal cancer who received regorafenib combined with toripalimab in the Second Affiliated Hospital of Nanchang University from June 2019 to January 2021. These patients had previously received at least second-line treatment; the regimens were oxaliplatin and irinotecan-based chemotherapy and/or accompanied with bevacizumab or cetuximab. Thirty-three patients were treated orally with regorafenib 80 mg or 120 mg once daily for 21 days, 28 days as a cycle, combined with intravenous toripalimab until disease progression or intolerant to adverse reactions. We used the Kaplan–Meier method to estimate the rate of progression-free survival (PFS) and log-rank method to do a statistical test of the survival curve. The Cox regression model was used to analyze the influence of multiple factors on PFS. The primary endpoints were objective remission rate (ORR) and disease control rate (DCR). The secondary endpoints were the incidence of adverse reactions and median progression-free survival (mPFS). Results. The evaluation of treatment effects was assessed according to RECIST 1.1. Four patients (12.12%) got partial response, twelve patients (36.36%) experienced stable disease, and seventeen patients (51.52%) suffered progressive disease. ORR was 12.12% and DCR was 48.48%. mPFS was 113 days (95% CI: 0–272.1). In univariate analysis, patients who had previously received second-line treatment were significantly better than those who had received third-line or more treatment ( p = 0.005 ). Lung metastasis was a negative factor in combined therapy ( p = 0.032 ). Five patients without previous treatment of bevacizumab were effective. Previous treatment without bevacizumab showed a trend of effective when combination therapy ( p = 0.034 ). It was also a positive factor that the Eastern Cooperative Oncology Group performance status (ECOG) score was 0 ( p = 0.034 ). Multivariable Cox regression analysis showed the number of previous chemotherapy lines and excision of primary lesions were independent prognostic factors. The most common treatment-related adverse reactions were hand-foot syndrome (33.33%), liver dysfunction (27.27), hypothyroidism (24.24%), fever (24.24%), fatigue (21.21%), leukopenia (15.15%), hypertension (12.12%), platelet count decreased (6.06%), diarrhea (3.03%), and myocarditis (3.03%); one patient stopped treatment as myocarditis. The incidence of grade 3/4 adverse reactions was 9.09%. Conclusions. Regorafenib combined with toripalimab has a promising effect in the third-line and beyond treatment of advanced colorectal cancer. In the early use of combination therapy, excision of primary lesions can have a positive impact in regorafenib and toripalimab combination. This treatment-related adverse reactions are tolerant in combined therapy.

Efficacy and Safety of Regorafenib As Beyond Second-Line Therapy in Patients with Metastatic Colorectal Cancer: an Adjusted Indirect Meta-Analysis and Systematic Review

Efficacy and Safety of Regorafenib As Third-Line Therapy in Metastatic Colorectal Cancer: an Indirect Meta-Analysis.

Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: a retrospective cohort study

Efficacy and Safety of Regorafenib and Fruquintinib As Third-Line Treatment for Colorectal Cancer: a Narrative Review

Comparison of Efficacy and Safety for Patients with Beyond Second Line Treated Metastatic Colorectal Cancer: a Network Meta-Analysis of Randomized Controlled Trials

Efficacy and Safety of Regorafenib in Combination with Chemotherapy As Second-Line Therapy in Patients with Metastatic Colorectal Cancer: A Network Meta-Analysis.

Comparison of the efficacy and safety of third-line treatments for metastatic colorectal cancer: a systematic review and network meta-analysis

A real-world study: third-line treatment options for metastatic colorectal cancer

Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer

Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi-Center Retrospective Study

Efficacy and Safety Comparison of Regorafenib and Fruquintinib in Metastatic Colorectal Cancer-An Observational Cohort Study in the Real World.

Regorafenib, TAS-102, or Fruquintinib for Metastatic Colorectal Cancer: Any Difference in Randomized Trials?

Treatment modalities of regorafenib and survival in metastatic colorectal (mCRC) patients: A real-world multicenter retrospective study.

Real‐world Effectiveness of Regorafenib in the Treatment of Patients with Metastatic Colorectal Cancer: A Retrospective, Observational Study

Single-center Retrospective Analysis of Second-Line Treatment with Regorafenib in Patients with Advanced Colorectal Cancer among the COVID-19 Pandemic.

Regorafenib with or Without a Programmed Cell Death Protein 1 Antibody As Third-Line Treatment for Microsatellite Stable Metastatic Colorectal Cancer

Practical Considerations in the Use of Regorafenib in Metastatic Colorectal Cancer

Contemporary Real-World Evidence in Unresectable HCC (uhcc) Patients Treated with Regorafenib in Taiwan: Interim Results from the Observational REFINE Study.

Efficacy and Safety of Regorafenib As Second-Line Treatment for Patients with Hepatocellular Carcinoma and Macrovascular Invasion And(or) Extrahepatic Metastasis

Efficacy and safety of regorafenib alone or in combinations in the second-line setting for advanced hepatocellular carcinoma: A multicenter real-world study.

Efficacy, treatment modalities, and safety of regorafenib in Chinese metastatic colorectal cancer patients: A multiple centers real-world study.